Johnson & Johnson Stock - Analyst consensus and strategy snapshot
17.06.2026 - 18:03:23 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 17:59 CET. Details in the imprint.
Johnson & Johnson (US4781601046) remains one of the largest healthcare groups globally by market value. With no new ad-hoc announcements or major filings today, investors are turning to the company’s strategy execution and the current analyst consensus as orientation.
Background and price data on Johnson & Johnson
Key figures, regulatory filings and past news on Johnson & Johnson stock are available in the ad hoc news topic overview and on the company’s investor relations site.
What analysts currently expect
Analyst coverage on Johnson & Johnson remains broad, reflecting its status as a Standard & Poor's 500 index bellwether. According to a consensus snapshot on a major financial data platform, the majority of analysts currently rate the stock at "Hold" or equivalent, with a minority recommending "Buy".
The average 12-month price target across these houses implies only a moderate upside from recent trading levels, underscoring a balanced view between pipeline potential and mature product exposure. Individual price targets from large banks such as JPMorgan, Goldman Sachs or Bank of America are spread over a relatively narrow range, signaling limited dispersion in expectations.
Operations, pipeline and strategy lens
From an operational perspective, Johnson & Johnson positions itself as a diversified healthcare company anchored in pharmaceuticals and medtech after the Kenvue consumer separation in 2023. An IR statement from 08/23/2023 on the Kenvue split outlines that strategic pivot toward higher-growth, higher-margin segments.
The Janssen pharmaceuticals unit focuses on oncology, immunology, neuroscience and cardiovascular indications among others, while the medtech division targets surgery, orthopedics, vision and interventional solutions. Management highlights a multi-year pipeline with late-stage assets as a key growth driver, alongside incremental innovation in established franchises.
How the company makes money
Johnson & Johnson today generates most of its revenue from patented pharmaceuticals and medical devices sold globally to hospitals, healthcare systems and specialists. The company emphasizes scale, broad geographic reach and a diversified portfolio to stabilize cash flows across cycles.
Where the stock trades today
Johnson & Johnson stock (US4781601046) trades on the New York Stock Exchange at around $145 per share as of 06/17/2026, 17:30 CET, reflecting its role as a large-cap US healthcare name.
Key facts on Johnson & Johnson stock
- Company: Johnson & Johnson Inc.
- ISIN: US4781601046
- WKN: 853260
- Ticker: JNJ
- Venue: NYSE
- Price (as of 06/17/2026, 17:30 CET): 145.00 USD
- Market cap: approximately 350,000,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Medical Devices
- Index membership: Dow Jones Industrial Average, S&P 500
- Next earnings date: 07/18/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
